Differential effects of natriuretic peptides on arterial and venous coronary artery bypass conduits

Hao G Nguyen1, Amit Korach, Chey Collura

  • 1Department of Cardiothoracic Surgery, Boston Medical Center, Boston, Massachusetts, USA.

Insights

Natriuretic peptides strongly relax arterial grafts, unlike venous grafts, via guanylyl cyclase and nitric oxide. This explains why arterial conduits offer superior patency in coronary bypass surgery.

Area of Science:

  • Cardiovascular Research
  • Vascular Biology
  • Pharmacology

Background:

  • Arterial grafts demonstrate superior patency rates compared to venous grafts in coronary bypass grafting (CABG) surgery.
  • Natriuretic peptides are key regulators of vascular homeostasis.
  • The differential effects of natriuretic peptides on arterial versus venous conduits remain to be elucidated.

Purpose of the Study:

  • To investigate the differential effects of natriuretic peptides on arterial and venous conduits used in CABG.
  • To explore the underlying mechanisms, including cyclic guanosine monophosphate (cGMP) and natriuretic peptide receptor (NPR) expression, mediating these effects.

Main Methods:

  • Segments of internal mammary artery, radial artery, and saphenous vein from CABG patients (n=12) were used.
  • Relaxation responses to atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide were measured.
  • Tissue cGMP levels, NPR expression (immunohistochemistry, Western blotting), and effects of guanylyl cyclase and nitric oxide synthase inhibitors were assessed.

Main Results:

  • Internal mammary artery and radial artery showed greater relaxation to natriuretic peptides than saphenous vein, with higher cGMP levels.
  • Relaxation was significantly reduced by guanylyl cyclase inhibitor LY83583 and modestly by nitric oxide synthase inhibitor N(G)-Nitro-L-arginine methyl ester.
  • NPR(A), NPR(B), and NPR(C) expression was significantly higher in arterial conduits compared to saphenous vein.

Conclusions:

  • Natriuretic peptides act as potent vasodilators for arterial conduits (internal mammary artery, radial artery) but not for venous conduits (saphenous vein).
  • The vasodilatory effects are mediated via the guanylyl cyclase and nitric oxide synthase pathways.
  • These findings offer insights into the superior patency of arterial grafts in coronary bypass surgery.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...